Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 6/20 | 0.34 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12549469 | 0.91 | DPP8 (0.38) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL12549530 | 0.83 | TRAP1 (0.37) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL12549188 | 0.78 | DPP8 (0.32) | DPP8DPP9DPP7 | |
| SCHEMBL12549189 | 0.75 | DPP8 (0.37) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL8043831 | 0.71 | DDB1 (0.36) | DPP8DPP9DPP7ABHD6DDB1 | |
| SCHEMBL12192457 | 0.69 | DDB1 (0.34) | DDB1CRBN | |
| SCHEMBL12192472 | 0.69 | DDB1 (0.34) | DDB1CRBN | |
| SCHEMBL8203249 | 0.68 | DPP8 (0.40) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL12192502 | 0.67 | DDB1 (0.34) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL3427494 | 0.67 | DPP8 (0.57) | DPP8DPP9DPP7TRAP1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110135599-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135599-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135599-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, HAVCR2 | DPP8 41/4885DPP9 76/4885DPP7 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.